Mirapexin®/Sifrol® (pramipexole)

Mirapexin®/Sifrol® (pramipexole):
>five million patient-years of experience in Parkinson's disease

Clinical evidence: motor symptoms

  • Mirapexin®/Sifrol® (pramipexole) is an effective treatment used to control the motor symptoms at all stages of Parkinson's disease (PD):
    • Mirapexin®/Sifrol® provides effective control of the core motor symptoms: rigidity (stiffness) leading to loss of facial expression, rest tremor (shaking of arms, legs or head), bradykinesia / akinesia (a slowness or absence of movement respectively) often resulting in shuffling gait1
    • Mirapexin®/Sifrol® has been shown to significantly improve tremor in patients with treatment resistant tremor2
  • As an adjunct to levodopa, Mirapexin®/Sifrol® enables patients to lead more active lives by reducing "off" time and improving motor function during "on" and "off" times.3,4 Periods of improved motor functioning are referred to as the "on" state and periods of reduced mobility, at the end of the dosing interval, as the "off" state
    • In addition, Mirapexin®/Sifrol® may prevent and control motor complications such as dyskinesia (involuntary jerking movements) related to levodopa, by delaying the need for levodopa and reducing levodopa dosage when combined with Mirapexin®/Sifrol®3,5

Back

View references

  1. Künig G et al. Pramipexole, a non-ergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharm 1999; 22: 301-305.
  2. Pogarell O et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713-720.
  3. Parkinson Study Group, Holloway RG et al. Pramipexole vs levodopa as initial treatment for Parkinson's disease. Arch Neurol 2004; 61(7): 1044-1053.
  4. Poewe W et al. Clinical efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease (CLEOPATRA-PD). Lancet Neurol 2007; 6(6): 513-520.
  5. Clarke CE et al. Pramipexole for levodopa-induced complications in Parkinson's disease (Review). Cochrane Database of Systematic Reviews 2006; 3: 1-19.

Close